Certara (CERT) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
9 Apr, 2026Executive summary
FY 2025 revenue reached $418.8M, up 9% year-over-year, with adjusted EBITDA of $134.5M, up 10%.
Q4 2025 revenue was $103.6M, a 3% increase year-over-year; adjusted EBITDA was $32.5M, down 3%.
Net loss for Q4 2025 was $5.9M, compared to net income of $6.6M in Q4 2024.
Jon Resnick was appointed CEO effective January 1, 2026, bringing over 30 years of experience and emphasizing operational discipline, customer-centricity, and AI-driven innovation.
2026 is positioned as a transition year, with operational improvements and a focus on sustainable, faster growth.
Financial highlights
FY 2025 GAAP revenue grew 9% year-over-year to $418.8M; Q4 2025 revenue was $103.6M, up 3%.
FY 2025 adjusted EBITDA was $134.5M (32% margin), up 10%; Q4 adjusted EBITDA was $32.5M (31% margin), down 3%.
FY 2025 adjusted net income was $70.9M; Q4 adjusted net income was $14.9M, down from $24.7M in Q4 2024.
FY 2025 adjusted diluted EPS was $0.44; Q4 adjusted EPS was $0.09, down from $0.15.
Cash and cash equivalents at year-end were $189.4M.
Outlook and guidance
FY 2026 revenue growth is projected at 0–4%, with Q1 expected at the low end due to tough comparison and acceleration anticipated in later quarters.
Adjusted EBITDA margin expected between 30–32%; adjusted diluted EPS guidance is $0.44–$0.48.
Fully diluted shares expected in the range of 160–162M; effective tax rate modeled at 30%.
Continued discretionary R&D investments planned, with $10M in cost avoidance identified for 2026.
Latest events from Certara
- Director elections, auditor ratification, and executive pay are key 2026 meeting topics.CERT
Proxy filing3 Apr 2026 - Virtual annual meeting to vote on directors, auditor, and executive pay, with board support.CERT
Proxy filing3 Apr 2026 - AI-driven product launches and disciplined cost control set the stage for cautious 2026 growth.CERT
Barclays 28th Annual Global Healthcare Conference10 Mar 2026 - 2026 guidance reflects stable markets, strong biosimulation growth, and operational transformation.CERT
Leerink Global Healthcare Conference 20269 Mar 2026 - Operational rigor, AI innovation, and cloud migration drive growth amid evolving regulatory and market dynamics.CERT
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - Strong biotech demand, AI-driven innovation, and cloud adoption fuel growth amid regulatory shifts.CERT
Stephens Annual Investment Conference3 Feb 2026 - Q2 revenue up 3% to $93.3M, net loss $12.6M, guidance reiterated at $385M–$400M.CERT
Q2 20242 Feb 2026 - Biosimulation and AI adoption accelerate, supported by acquisitions and a unified cloud platform.CERT
Jefferies Global Healthcare Conference1 Feb 2026 - AI-driven software growth and stable services underpin a broad biosimulation market opportunity.CERT
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026